Gene Therapy





BlueBackground_workshops-hero-size.jpg
Media Partner:
BZ_2017-RGB-3000-x-738.jpg

Summary

This workshop focuses on the rapidly evolving and complex Advanced Therapeutics and Medicinal Products (ATMP) field. ATMPs encompass a wide range of therapies, from gene and cell therapies to gene editing technology. While there has been exciting progress in the preclinical and clinical stages in recent years, this success does not necessarily equal commercial success.

This workshop brings together different perspectives from academic, industry, and regulatory fields to discuss and clarify the main issues confronting ATMP development, and offers a broad overview of the challenges of developing ATMP therapies. Topics will include adoption challenges, clinical provisions, supply chains, manufacturing,and health economics.

Join us to hear and discuss the latest in the discovery and early development breakthroughs and case studies on:

  • Gene editing technology
  • Innovation in manufacturing
  • Product testing and quality control
  • Diversity in disease
  • Perspectiveson clinical opportunities
Learning Objectives
This event helps participants develop a better understanding of the ATMP ecosystem by fostering discussion and the identification of opportunities for collaboration,and by providing networking opportunities with a range of key experts including individuals from start-ups, academia, industries, CMO, regulatory, and clinical environments.

Participants in this event will:
  • Understand the current cell and gene therapy pipelines across disease areas
  • Discuss recent breakthroughs in gene editing approaches, especially on advancing non-viral vectors for ex vivo/in vivo gene editing
  • Discover key preclinical development and testing work packages to enable rapid clinical translation of cell and gene therapy products
Sponsored By:

charles_river_logo.jpg

Registration Information

 

Registration Type Early Registration
(April 1–August 13, 2019) 
On-site Registration
(August 14-September 5, 2019)
Member $1,095 $1,395
Non-member $1,395 $1,595
Student $150 $250

Registration Fee Includes:

    • Access to the session slides post event
    • Buffet lunch daily
    • Morning and afternoon beverage breaks
    • Evening Reception 

Cancellations

If you cancel registration on/before, August 19, 2019 you will be refunded your registration fee minus an administration fee of $50.

No refunds will be given for “no shows” or for cancellations received on or after August 20, 2019.

Refunds will be credited back to the original credit card used for payment, or if paid by check, a refund check will be issued to the original payer within 30 days of submission.

Substitutions

Registration substitutions from the same company may be submitted in writing to [email protected] at any time without penalty. If the membership status of the substitute differs from that of the original registrant, a refund or additional charge at the current rate may apply.


Location

Hilton London Tower Bridge
5 More London Place,
Tooley Street
London, SE1 2BY, United Kingdom
+44.203.002.4300

Maps & Directions

If you are travelling by tube or train, leave the London Bridge Station via the exit marked towards London Bridge, cross the street and turn right. Walk straight for just 2 minutes and you will have reached the Hilton London Tower Bridge.

Closest Airports:

  • 18 miles-Heathrow Airport
  • 6 miles-City Airport
  • 28 miles-Gatwick Airports

Featured Speakers

DavidProfessor Anna David Ph.D., FRCOG, is Director of the Elizabeth Garrett Anderson Institute for Women’s Health at University College London, UK. She is also Honorary Consultant in Obstetrics and Maternal Fetal Medicine at UCL Hospital. Her clinical practice specializes in fetal medicine, severe congenital disease, fetal growth restriction and prevention of preterm birth. Her research team at UCL is developing novel prenatal therapies using stem cells and gene therapy, for severe and life-threatening obstetric conditions and congenital disease. She leads a European Commission FP7 funded consortium “EVERREST” that is translating into the clinic an adenovirus vector maternal growth factor gene therapy for severe fetal growth restriction. This 6 year program has explored the bioethics of gene therapy in pregnancy, performed preclinical efficacy and reproductive toxicology studies and developed a first-in-woman clinical trial. Anna leads UCL as a partner in a European Commission Horizon 2020 funded consortium “BOOSTB4”, that has regulatory and ethical approval to start the first clinical trial of in utero stem cell transplantation for osteogenesis imperfecta, a severe congenital skeletal dysplasia. She coordinated the introduction of fetal surgery for spina bifida to the UK in 2018 and co-leads the UCL Centre for Prenatal Therapy.

speaker

Stefanos Theoharis, Ph.D., joined Cell Medica to lead its partnering activities, bringing a combination of academic, business development, project management and finance skills.

Following his PhD, Stefanos worked as a post-doctoral researcher at Imperial College, whilst also working for six years in parallel as a paid consultant to the London Technology Network, a government-funded organization bridging the gap between industry and academia. Subsequently, Stefanos joined Lazard, the investment bank, as a member of the life science M&A team and then Roche Partnering, as Director of Emerging Technologies, where he participated in multiple licensing deals, with a focus on novel innovative technologies. He then joined Antisense Pharma as Head of BD. Prior to joining Cell Medica, Stefanos was CBO for apceth in Munich, where he was responsible for business development on the company’s first-in-man engineered cell therapy platform and its GMP manufacturing business, as well as project management, and communications.

Stefanos holds a PhD in gene therapy and immunology and a MSc in Molecular Medicine both from Imperial College.

speaker

 Claire Brady Ph.D., is the Network Programme Manager for the Northern Alliance Advanced Therapy Treatment Centre (NA-ATTC).  The goal of the programme is to bring together the NHS, industry and the public sector to develop the necessary processes, skilled staff and infrastructure, at scale, as more ATMP treatments move from clinical trial to marketed products.

Prior to joining the Catapult, Claire established the Technology Transfer team for Edinburgh Innovations, one of the UK’s leading IP commercialisation offices.  Claire has over fifteen years’ experience of taking new early stage ground-breaking technology to market - typically via licensing, collaboration, or formation of new venture capital backed spinout companies - giving her fully rounded experience of what is required to take disruptive products from the bench to bedside.

Claire graduated from UMIST with a Biochemistry degree after which she spent four years in a specialist translational research institute, the Paterson Institute for Clinical Research, where she obtained a PhD in oncology.  The early part of Claire’s career was spent as a research scientist for a small biotech company where she developed new expression technology for gene therapy applications.

speaker

Rob Dodge Ph.D., has worked in the Pharmaceutical Industry for over 20 years in both CMC manufacturing and analytical release of Biologic therapeutics and regulated Bioanalytical testing of small molecules, protein drugs, biomarkers and novel molecular entities such as nucleic acids, cell therapy, and gene therapy products.  Rob started his professional career at Bristol-Myers Squibb in the Immunology Department of the Pharmaceutical Research Institute and then moving to the biologic drug development and characterization team and finally to the Bioanalytical team where he was recently the Director of Bioanalytical Sciences Development leading a team of scientists developing bioanalytical assays to support regulated bioanalysis for pharmacodynamics and immunogenicity assessments.   Rob is currently the Discovery Bioanalytical Global Lead at Novartis supporting assay development and bioanalytical testing using LC/MS/MS, LBA, qPCR, flow cytometry and cell based bioanalytical platforms for small molecules, biologics, nucleic acids and gene therapy therapeutics. 


Program Committee

  • Sanyogitta Puri, Ph.D., AstraZeneca
  • Pamela Tranter, Ph.D., University College London
  • Chad Briscoe, Ph.D., PRA Health Sciences
  • Jonathan Clarke, M.D., Procella
  • Anna Outhwaite, Catapult